RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer.

doi:10.1038/s41591-022-01976-z

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer.

Nature medicine - 1 Oct 2022

Elez Elena, Ros Javier, Fernández Jose, Villacampa Guillermo, Moreno-Cárdenas Ana Belén, Arenillas Carlota, Bernatowicz Kinga, Comas Raquel, Li Shanshan, Kodack David Philip, Fasani Roberta, Garcia Ariadna, Gonzalo-Ruiz Javier, Piris-Gimenez Alejandro, Nuciforo Paolo, Kerr Grainne, Intini Rossana, Montagna Aldo, Germani Marco Maria, Randon Giovanni, Vivancos Ana, Smits Ron, Graus Diana, Perez-Lopez Raquel, Cremolini Chiara, Lonardi Sara, Pietrantonio Filippo, Dienstmann Rodrigo, Tabernero Josep, Toledo Rodrigo A

Abstract excerpt

Anti-BRAF/EGFR therapy was recently approved for the treatment of metastatic BRAFV600E colorectal cancer (mCRCBRAF-V600E). However, a large fraction of patients do not respond, underscoring the need to identify molecular determinants of treatment response. Using whole-exome sequencing in a discovery cohort of patients with mCRCBRAF-V600E treated with anti-BRAF/EGFR therapy, we found that inactivating mutations in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Cancer Treatments and Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to ErbB Receptors

Share to Lung Cancer Treatments and Mutations

Share to Microsatellite Instability

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Ubiquitin-Protein Ligases

Source

Open in PubMed Open full text

Identifiers

PMID: 36097219
DOI: 10.1038/s41591-022-01976-z
PMCID: PMC9556333

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer.PMID 36097219Read ↗

BRAF V600E and RNF43 Co-mutations Predict Patient Outcomes With Targeted Therapies in Real-World Cases of Colorectal Cancer.Semantic proximity Read ↗

Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable BRAFV600E-Mutated Metastatic Colorectal Cancer Treated With Target Therapy or Chemotherapy.Semantic proximity Read ↗

Association of RNF43 Genetic Alterations With BRAFV600E and MSIhigh in Colorectal Cancer.Semantic proximity Read ↗

Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers.Semantic proximity Read ↗

Exome sequencing revealed comparable frequencies of RNF43 and BRAF mutations in Middle Eastern colorectal cancer.Semantic proximity Read ↗

RNF43 G659fs is an oncogenic colorectal cancer mutation and sensitizes tumor cells to PI3K/mTOR inhibition.Semantic proximity Read ↗

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitorsSemantic proximity Read ↗

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.Semantic proximity Read ↗

The Evolving Treatment Landscape in BRAF-V600E-Mutated Metastatic Colorectal Cancer.Semantic proximity Read ↗

Rnf43 Mutation As A Biomarker For Immune Checkpoint Inhibitor Efficacy In Colorectal CancerSemantic proximity Read ↗

DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations.Semantic proximity Read ↗

Commonly observed RNF43 mutations retain functionality in attenuating Wnt/β-catenin signaling and unlikely confer Wnt-dependency onto colorectal cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.